

Remedy Pharmaceuticals Successfully Completes Phase 1 Study

Important development milestone is met with conclusion of safety study

New York, NY, USA - September 25, 2010 – Remedy Pharmaceuticals, Inc. today announced that its Phase 1 study titled “A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of RP-1127 in Healthy Male and Female Volunteers” has been successfully completed.

The study, designed to evaluate the safety and tolerability of different dose levels of RP-1127 administered as a bolus dose followed by a 3-day continuous infusion, evaluated 34 healthy volunteers enrolled at the Jasper Clinic in Kalamazoo, MI. Study subjects were housed in the Jasper in-patient facility to allow for continuous safety monitoring. There were no serious adverse events during the study.

“Completing this Phase 1 is an important step towards future efficacy studies,” said Sven Jacobson, Chief Executive Officer of Remedy. “We are delighted by the outcome of the study, and this initial evidence indicates that RP-1127 has a high likelihood of being safe and well tolerated in patients suffering from our targeted indications such as stroke, traumatic brain injury and spinal cord injury.”

Detailed information for this study is available at:
<http://clinicaltrials.gov/ct2/show/NCT01132703>

About RP-1127

Remedy’s lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca-ATP} channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com